Chemical Properties:
Package: Bottle, Aluminum foil bag, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureCommercial Supply (CAS: 177036-94-1) Related Intermediates: CAS: 177036-94-1 Methyl 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoate CAS: 178306-47-3 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid CAS: 178306-51-9 (S)-2-Hydroxy-3-Methoxy-3,3-Diphenylpropionic Acid CAS: 178306-52-0 L-Proline Methyl Ester Hydrochlorid CAS: 2133-40-6 4,6-Dimethyl-2-(Methylsulfonyl)pyrimidine CAS: 35144-22-0| Item | Specifications |
| Appearance | White or Off-White Powder |
| Purity | ≥99.0% (HPLC) |
| Moisture (K.F) | ≤1.00% |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.00% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of API (CAS: 177036-94-1) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid |
| CAS Number | 178306-51-9 |
| CAT Number | RF-PI161 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C16H16O4 |
| Molecular Weight | 272.3 |
| Density | 1.248 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid (CAS: 178306-51-9) with high quality, it's a key intermediate of API (CAS: 177036-94-1). (CAS: 177036-94-1) is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. It is the third ET-receptor antagonist to be marketed for this indication behind bosentan and sitaxsentan. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting.
